Clinical Trial

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3122 Capsules in Subjects With Advanced Malignant Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is the first-in-human clinical study of TQB3122, aiming to evaluate the safety, tolerability, and pharmacokinetic characteristics of TQB3122 in advanced solid tumors, and to preliminarily explore its efficacy in solid tumors.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-26.
Status change: Not Yet Recruiting → Recruiting 2026-01-27
Trial Details
NCT Number NCT07269145
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions Advanced Cancer
Enrollment 86 participants
Start Date 2026-01-22
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-28